Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
02 February 2007Website:
http://www.championsoncology.comNext earnings report:
24 July 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Wed, 03 Jul 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
CSBR Latest News
HACKENSACK, NJ / ACCESSWIRE / March 6, 2024 / Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the third quarter ended January 31, 2024, on Tuesday, March 12, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.
Champions Oncology, Inc. (NASDAQ:CSBR ) Q2 2024 Earnings Conference Call December 12, 2023 4:30 PM ET Company Participants Ronnie Morris - CEO David Miller - CFO Operator Greetings. Welcome to the Champions Oncology Second Quarter Fiscal Year 2024 Earnings Call.
HACKENSACK, NJ / ACCESSWIRE / December 4, 2023 / Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the second quarter ended October 31, 2023, on Tuesday, December 12, 2023, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.
HACKENSACK, NJ / ACCESSWIRE / July 20, 2023 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the fourth quarter and year ended April 30, 2023, on Monday, July 24, 2023, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.
What type of business is Champions Oncology?
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
What sector is Champions Oncology in?
Champions Oncology is in the Healthcare sector
What industry is Champions Oncology in?
Champions Oncology is in the Biotechnology industry
What country is Champions Oncology from?
Champions Oncology is headquartered in United States
When did Champions Oncology go public?
Champions Oncology initial public offering (IPO) was on 02 February 2007
What is Champions Oncology website?
https://www.championsoncology.com
Is Champions Oncology in the S&P 500?
No, Champions Oncology is not included in the S&P 500 index
Is Champions Oncology in the NASDAQ 100?
No, Champions Oncology is not included in the NASDAQ 100 index
Is Champions Oncology in the Dow Jones?
No, Champions Oncology is not included in the Dow Jones index
When does Champions Oncology report earnings?
The next expected earnings date for Champions Oncology is 24 July 2024